IMM01
- Generic Name
- IMM01
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG 1 fusion protein. IMM01 is under investigation in clinical trial NCT05140811 (A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome).
- Associated Conditions
- -
- Associated Therapies
- -
CD47 Targeted Cancer Immunotherapy Drugs Clinical Trials FDA Approval Insight
Kuick Research predicts the first CD47 targeting drug will be approved by 2029. The report highlights global market opportunities, insights on over 100 CD47 inhibitor drugs in clinical trials, and key developments in CD47 inhibitor drugs. CD47-targeted therapies aim to enhance the immune system's natural defense against cancer cells, with multiple antibodies in development. The CD47 market is expanding rapidly due to the rising incidence of cancer and increased clinical research.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath